A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection
DW Borhani, DJ Calderwood, MM Friedman… - Bioorganic & Medicinal …, 2004 - Elsevier
DW Borhani, DJ Calderwood, MM Friedman, GC Hirst, B Li, AKW Leung, B McRae…
Bioorganic & Medicinal Chemistry Letters, 2004•ElsevierA-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection -
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Search
RegisterSign in View PDF Download full issue Search ScienceDirect Elsevier Bioorganic &
Medicinal Chemistry Letters Volume 14, Issue 10, 17 May 2004, Pages 2613-2616 Bioorganic &
Medicinal Chemistry Letters A-420983: a potent, orally active inhibitor of lck with efficacy in a
model of transplant rejection Author links open overlay panel David W. Borhani , David J …
ScienceDirect Skip to main contentSkip to article Elsevier logo Journals & Books Search
RegisterSign in View PDF Download full issue Search ScienceDirect Elsevier Bioorganic &
Medicinal Chemistry Letters Volume 14, Issue 10, 17 May 2004, Pages 2613-2616 Bioorganic &
Medicinal Chemistry Letters A-420983: a potent, orally active inhibitor of lck with efficacy in a
model of transplant rejection Author links open overlay panel David W. Borhani , David J …
We have identified the pyrazolo[3,4-d]pyrimidine A-420983 (compound 7) as a potent inhibitor of lck. A-420983 exhibits oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.
Elsevier
